



## Cumulative Index

### Volume 47

---

January	MINORITY ORAL HEALTH, pages 1–186
April	NUTRITION AND ORAL HEALTH, pages 187–430
July	INFECTIONS, INFECTIOUS DISEASES AND DENTISTRY, PART I, pages 431–604
October	INFECTIONS, INFECTIOUS DISEASES AND DENTISTRY, PART II, pages 605–774

---

*Note:* Page numbers of article titles are in **boldface** type.

### A

---

- Abscess, mandibular, gram-positive staphylococci in, 615
- Acquired immune deficiency syndrome. See AIDS.
- Acyclovir, in herpes zoster, 523
- African American(s), children, prevalence of *Streptococcus mutans* in, 89  
in New York City, prevalence of dental caries among, **57–65**  
male, study of untreated syphilis in, 4–5  
maternal transmission of *Streptococcus mutans* in, **87–101**  
preterm low birth weight and periodontal disease among, **115–125**  
urban, incidence of orofacial injuries in, 141
- Aging, functional factors of, affecting nutritional status, 358  
physiologic factors of, affecting nutritional status, 356–357  
psychosocial factors of, affecting nutritional status, 357–358
- AIDS, 467  
incidence of, 468  
non-Hodgkin's lymphoma in, 541–542  
periodontal disease and, 160  
reporting of cases of, 467  
US surveillance data on, 468
- Airborne transmission, of occupationally acquired infections, 642
- Alcohol, as influence on nutritional status, 358–359
- American Dental Association, role of dentistry in bioterrorism and, 733  
statement on water used in dental treatment, 553
- Amino acids, 195–196
- Anabolic steroids, 251
- Anorexia nervosa, diagnostic criteria for, 397  
incidence of, 397  
physical symptoms of, 398  
systemic problems associated with, 390–391
- Anthrax, 736–738  
cutaneous, 738  
gastrointestinal, 737–738
- Antibiotic efflux pumps, multidrug, 631
- Antibiotic prophylaxis, as benefit to doctor, 675  
financial aspects of, 674–675  
for immunocompromised patients, 675  
for patients at risk for oral metastatic infections, 675  
for reduction of bacteremias, 671–673  
in immune deficiency, 727  
nonvalvular cardiovascular devices and, 675  
principles of, 666–668  
problems associated with, **665–679**  
surgical indications for, 666, 667  
to prevent bacterial endocarditis, 665

- Antibiotic resistance, **623-639**  
definition of, 632  
dentistry and, 633-635  
development of, 634-635  
transposable, 628-629
- Antibiotics, beta-lactam, viridans group streptococci and, 626  
enzymatic inactivation of, 630  
ideal duration of use of, 635  
inappropriate use in dentistry, 633-634  
macrolide, resistance to, 627  
mechanisms of action of, 627-628  
microbial resistance to, mechanisms of, 629-633  
"new," 632  
"recycling" of, 633  
resistance of *Streptococcus viridans* to, 673
- Antifluoridationists, 228-229
- Antiretroviral therapy, highly active, in HIV disease, 472-473, 477, 483  
oral side effects of, 473, 474  
toxicities associated with, 473-474
- Antitubercular therapy, drug interactions in, 461
- Arthritis, rheumatoid, and periodontitis, 584-585  
treatment of, 585
- Atherosclerosis, oral infections and, 575
- B**
- B-cells, 642-643
- Bacille Calmette-Guérin vaccine, 455
- Bacillus anthracis*, 733, 736-737
- Bacteremia(s), incidence of, 668-669  
oral cavity and, 668-669  
reduction of, antibiotic prophylaxis and, 671-673  
viridans group streptococci, 626
- Bacteria, and systemic conditions with susceptibility to infection, 551  
as building blocks of biofilms, 546  
cariogenic, xerostomia and, 320  
cultures, sensitivity pattern of, antibiotic discs and, 617  
gram-negative heterotrophic, in water, 546  
in dental waterlines, 548-549  
entry into patient during dental procedures, 550  
potential pathogenicity of, 549  
oral, and diet, 320  
pneumonia and, 583-584
- Bacterial challenge, subgingival, host response to, among ethnic/racial group, 110-111
- Bacterial cultures, from maxillofacial infections, media for culture of, 611  
processing of, problems associated with, 619
- Barrier techniques, to prevent transmission of tuberculosis, 460-461
- Beta-lactamase enzyme, 630
- Beta-lactamases, 630
- Beverages, fluoride content of, 233
- Binge eating disorder, 400
- Biofilm(s). See also *Bacteria*.  
and dental equipment design, 547-548  
definition of, 546  
nature of, 546-547  
quorum sensing and, 547
- Biological agents, 736-740  
CDC categories of, 736
- Biological warfare, history of, 734-735
- Biomedical research, recruitment for, access to health care and, 7  
confidence in efficacy of treatments and, 8  
difficulties in, 4  
educational level and, 8  
potential unpleasantness of, interventions and, 7
- Biopsies, for diagnosis of Creutzfeldt-Jakob disease, 507, 510-511
- Bioterrorism, dentistry and, **733-744**  
increasing threat of, 735  
responding to, dentistry's role in, 741-743
- Bioweapons, 735
- Bisphosphonates, 220
- Blood, occupational exposures to, prevention of, 684-685  
occupational transmission of pathogens in, risk of, 682-684
- Blood count, complete, 268-271, 272
- Blood dyscrasias, 719
- Blood products, Creutzfeldt-Jakob disease and, 502

- Blood tests, for diagnosis of  
 Creutzfeldt-Jakob disease, 506
- Bloodborne infectious disease, healthcare workers with, American College Health Association and, 751  
 American Dental Association and, 750  
 Centers for Disease Control and Prevention and, 745-746, 747-748  
 disability antidiscrimination laws and, 752-755  
 employment discrimination cases against, 753-754  
 legal issues for, **745-756**  
 precautions for, 748  
 risk for transmission, 745-746, 748-749  
 Society for Healthcare Epidemiology of America, 750-751  
 occupationally acquired, 642
- Body mass index/weight-for height ratio, for children, 280-281
- Bone, calcium in, 213-215  
 effects of parathyroid hormone and calcitonin on, 215, 216  
 formation and resorption of, 213-214  
 health of, and periodontal disease, 215
- Bone density, total body, 219
- Bovine spongiform encephalopathy, 493, 495
- Bulimia nervosa, diagnostic criteria for, 399  
 incidence of, 398-399  
 medical consequences of, 399

## C

- Caffeine, 251  
 and ephedra, 251
- Calcitonin, 213, 214  
 and parathyroid hormone, effects on bone, 215, 216
- Calcium, 247  
 absorption of, 210-212  
 and osteoporosis, 218-219  
 dietary, and periodontal disease, 317  
 domains in vertebrate body, 209  
 duodenal cell and, 211-212  
 excretion of, 217-219  
 foods rich in, 210  
 homeostasis, 212-213  
 in bone, 213-215  
 in luminal fluid, 210-211  
 in mammals, 209  
 in plasma, 212-213  
 parathyroid hormone and, 213  
 in teeth, 215-217  
 nutrition and metabolism of, **209-224**  
 sources of, 247  
 transcellular movement of, 211
- Cancer, development of, dietary compounds and, 414  
 incidence of, vegetable and fruit consumption and, 415
- Cancer patient, nutritional status of, 385-386
- Cancrum oris. See *Noma*.
- Candidiasis, oral pseudomembraneous, of buccal mucosa, 476
- Capsaicin, 252
- Carbohydrates, 191-193  
 classifications of, 192, 324  
 recommendations for diet, 192  
 sugars, and sweeteners,  
 caries-promoting potential of, 322, 323
- Cardiovascular disease, and periodontitis, 575-577  
 epidemiologic studies in, 576, 578-579, 580, 581  
 treatment of, 577  
 atherosclerosis in, 575  
 pathogenesis of, 576-577  
 risk factors for, 575-576
- Caries. See *Dental caries*.  
 dental. See *Dental caries*.
- Cell mediated deficiencies, 713
- Cellular immunity, impaired, pathogens associated with, 711
- Central nervous system, transmissible spongiform encephalopathies and, 500, 502-503
- Charles Drew University of Medical Sciences, 127, 178
- Chemotherapy, in tuberculosis, 457
- Chickenpox, 522
- Child(ren), African American, prevalence of *Streptococcus mutans* in, 89  
 caries in, dairy products and, 325-326  
 disorders in, nutrition-related, 287  
 emotional development of, and foods for, 285-286  
 food choices of, 294-295  
 environmental influences on, 286

- Child(ren) (*continued*)  
  food environment and, 296-297  
  HIV-infected, oral manifestations in,  
    clinical implications of, **159-174**  
  nutrient requirements of, 281-284  
  obesity in, 289-291  
  physical development of, and foods  
    for, 284-285  
  snacking and drinking by, 295-296  
  weight and height assessments in,  
    280-281
- Chlorhexidine, treatment using, effect on  
  maternal transmission of *Streptococcus*  
  *mutans*, 96-97
- Chronic wasting disease, 495
- Cleft lip/cleft palate, closure of,  
  postssurgical feeding and, 309-312  
  dental disease in children with, 313  
  etiology of, 305-306  
  impact on nutritional health and  
    oral-motor development,  
    **305-317**  
  infants with, breast feeding and,  
    312-313  
  nutritional requirements of,  
    307-312  
  oral-motor development in, 306-307
- Coenzyme Q10, 250
- Committee on Diet and Health, 187
- Committee on Dietary Allowances, 187
- Complement deficiencies, pathogens  
  associated with, 711, 713, 714
- Condyloma acuminatum, human papilloma  
  virus-associated, 477, 482
- Consumption. *See Tuberculosis.*
- Cranial nerve, impaired function of,  
  nutritional status and, 268, 270
- Creatine, 251-252
- Creutzfeldt-Jakob disease, acquired,  
  498-501  
  Kuru, 498  
  transmission of, 501-502  
  vCJD, 499-501  
  as transmissible spongiform  
  encephalopathy, 493  
  associated with dental treatment,  
    503-504, 506, 507-508  
  clusters of, 504  
  diagnosis of, 505-509  
  identification of patients with, 508  
  in exposure to bovine spongiform  
  encephalopathy, 499  
  incidence of, 497  
  inherited, 498  
    clinical features of, 498  
  maxillofacial surgery in, 511  
  percutaneous exposure to fluids of  
    patients with, 510  
  persons at risk of developing, 509-510  
  possible causes of, 497-498  
  suspected cases of, management of,  
    509  
  symptoms of, 497
- Cyclosporin, 723
- Cystic fibrosis, susceptibility to infections  
  and, 551
- Cytokines, in wound healing, 374-377
- Cytomegalovirus, 540-541  
  as clinical marker for AIDS, 525  
  infection with, diagnosis of, 525  
    in immunosuppressed patients,  
      524  
  in neonates, 524  
  treatment of, 526  
  transmission of, 524
- Cytotoxic drugs, neutropenia and, 716
- 
- D**
- Dairy products, childhood caries and,  
  325-326
- Delta hepatitis, 660
- Dental caries, analysis of, in HIV-infected  
  children, 161  
  and composition of whole saliva in  
    minority populations, **67-85**  
  causes of, 159  
  diet and, synergy between, 319-321  
  early childhood, 287-288  
  in eating disorders, 402-403  
  nutrition and, **319-336**  
  prevalence among African Americans  
    in New York City, **57-65**  
  study of, clinical implications of,  
    63-64  
    data analysis in, 60  
    discussion of, 62  
    methods of, 59-60  
    results of, 60-62  
  prevention of, dietary factors in,  
    325-327  
    fluoride in, 225, 227-228  
  promotion of, dietary factors in,  
    321-325
- Dental disease, in children with clefts, 313
- Dental equipment, design of, biofilms and,  
  547-548

Dental health, diet and, 269-261  
of older adults, 360

Dental office, waterborne infections and, 545

Dental practitioners, practice points for, 255

Dental prevention programs, in eating disorders, 405-407

Dental schools, recruitment of minorities to, 35

Dental treatment, complications from, in HIV disease, 483-486  
risk of bacterial endocarditis due to, 670-671

Dental waterlines. See *Waterlines, dental*.

Dentin, hypersensitivity of, in eating disorders, 403

Dentist(s), ethnicity of population and, 30  
illness of, due to exposure to contaminated dental treatment water, 552-553  
role in response to bioterrorism, 741-743  
transmission of tuberculosis by, 460  
visits to, by race/ethnicity, 33-36

Dentoalveolar surgery, dietary considerations and, 382-384

Dentures, diet suggestions in use of, 364-365, 366  
effect on food choices and general health, 361-362  
effect on taste, swallowing, and chewing, 360-361

Diabetes mellitus, and periodontitis, 585-586  
treatment of, 586  
dental treatment in, 389-390

Diet(s), and dental caries, synergy between, 319-321  
and dental health, 269-261  
and nutrition, evaluation of, 271-275  
in pediatric dentistry, **279-303**  
effects on periodontal health, 349-351  
habits, and oral health, 294-297  
of older adults, recommendations for, 362-366  
oral bacteria and, 320  
pediatric, guidelines for, 281-286  
recommendations for, for caries prevention, 327-328  
to combat obesity, 415-421

Diet and health guidelines for Americans, 189, 190

Dietary counseling, for prosthodontic patients, **355-371**  
in pediatrics, 297-300

Dietary education, and dietary screening, in dental practice, 328-332

Dietary factors, in prevention of caries, 325-327  
in promotion of caries, 321-325

Dietary reference intakes, 187-189

Dietary screening, and dietary education, in dental practice, 328-332  
for older adults, 362

Dietary supplement(s), certification of, 246  
definition of, 245-246  
medications and, 265

Disinfection, methods of, 702-703  
of patient care items, infections and, 699-700

DNA oncogenic viruses, 535-541

Dwarfism, psychosocial, 292

## E

Eating, disordered, 292-293  
subconscious, 296

Eating disorders, dental prevention programs in, 405-407  
oral manifestations of, 400-405  
recognition and management of, in dental office, **395-410**  
systemic problems associated with, 390-391

Echinacea, 252

Electroencephalogram, for diagnosis of Creutzfeldt-Jakob disease, 506

Encephalopathy(ies), bovine spongiform, 493, 495  
scrapielike spongiform, 495  
transmissible mink, 495  
transmissible spongiform, agents, inactivation of, 508  
and dentistry, 503-504  
animal, 493, 495  
Creutzfeldt-Jakob disease as, 493  
description of, 493  
infection control and dental treatment in, 505, 507-508, 509  
infectious agents in, 494-495  
orofacial manifestations of, 503  
pathogenesis of, 501  
prions and, **493-516**  
treatment of, 503

- Endocarditis, bacterial, absolute risk rate for acquiring, 671, 672  
antibiotic prophylaxis to prevent, 665  
oral micro-organisms and, 669-670  
periodontal disease and, 669  
prevention of, best case scenario for, 673  
risk of, due to dental treatment, 670-671  
*Streptococcus viridans* and, 668, 669  
infective, and oral bacteria, 577-583  
bacteria causing, 582  
conditions predisposing to, 582  
dental treatment and, 583  
pathogenesis of, 582  
treatment of, 582
- Endotoxin, 551  
results of exposure to, 551-552
- Enteral feeding, for surgical patient, 386-388
- Environmental factors, and health behavior, 25, 26-28
- Enzyme-linked immunosorbent assay, 470
- Eosinophils, 642
- Epstein-Barr virus, neoplasms associated with, 538-539  
oral hairy leukoplakia and, 527  
transmission of, 539
- Epstein-Barr virus infection, chronic active, 526  
malignancies associated with, 526-527  
symptoms of, 526
- Ergogenic acids, 250-252
- Erythema multiforme, recurring, recurrent herpes simplex virus and, 520
- Ethambutol, in tuberculosis, 457  
side effects of, 462

---

**F**

- Failure to thrive, protein energy malnutrition and, 288-289
- Fat(s), daily requirements of, 194-195  
dietary, 193-194  
oral health and, 195  
polyunsaturated, 194
- Fat substitutes, 195
- Fluid hydration, for surgical patient, 388-389

- Fluoride(s), added to water, 225, 226-229  
daily ingestion of, 235-236  
dietary supplements, 229-230  
in caries prevention, 225, 227-228  
role in nutrition, **225-243**  
sources in diet, 232  
therapeutic, 226-232  
to treat osteoporosis, 220-221  
toxicity, 236-238

- Fluoroquinolones, resistance to, viridans group streptococci and, 627

- Fluorosis, skeletal and dental, 236-238

- Food(s), choices of, for children, 294-295  
fluoride content of, 232-233  
functional, 411-413  
examples of, 412  
rationale for, 412-413  
labels on, 190

- Food environment, children and, 296-297

- Food guide pyramid, 189, 191

- Food pyramid, for older adults, 363, 366

- Forsyth Institute laboratories, 179

- Fructose, malabsorption of, 291-292

---

**G**

- Garlic, 252-253

- Gingival disease, in HIV disease, 482, 483

- Gingivitis, 337-338

- acute necrotizing, incidence of, 560-561  
precursor to noma, 559-560, 564-565  
necrotizing ulcerative, fusobacteria and spirochetes in, 616

- Ginseng, 253

- Granulocytopenia, 719, 722

- Green tea, 253

- Growth, definition of, 202  
nutrients and, 202

- Growth and development, normal, 279-281

- Growth factors, in wound healing, 377-378

- Guarana, 253

---

**H**

- Hairy leukoplakia, 476, 477  
Epstein-Barr virus and, 527

- Head and neck, tuberculosis of, 453
- Health, and health behavior, models for studying, 24-26  
determinants of, 22-24  
promotion of, nutrition for, **411-423**
- Health behavior(s), and health, models for studying, 24-26  
and health perceptions, understanding of, **21-39**  
environmental factors and, 25, 26-28  
predictors of, 25
- Health care facility, transmission of tuberculosis in, risk categories for, 460
- Health care issues, promotion of, minorities in communications professions and, 35-36
- Health care provider(s), and  
patient-provider issues, 29  
bloodborne infectious disease in. See *Bloodborne infectious disease, healthcare workers with.*  
future vaccinations for, 660-661  
immunizations and, **641-664**  
contraindications, precautions, and adverse reactions to, 657-658  
immunocompromised, vaccine considerations for, 658-660  
immunoprophylaxis for, recommended, 647, 648  
professions included as, 646  
specific vaccines for, 649-657
- Health insurance, by race/ethnicity, 27-28
- Health perceptions, and health behaviors, understanding of, **21-39**
- Heavy metals, antibiotic resistant genes and, 632
- Hematopoietic cell transplant, 721  
posttransplant complications of, 721-722
- Hepatitis, acute, hepatitis A as cause of, 436  
causes of, 432  
chronic, hepatitis B as cause of, 437  
definition of, 431  
human viral, advances in diagnosis and management of, **431-447**  
chronic, 433-434  
diagnosis of, 432-434  
blood test for, 432-433  
imaging techniques for, 432  
liver function tests in, 433  
HIV disease and, 475  
pathogenesis of, 434-443  
symptoms of, 431  
systems affected by, 434  
types of, 434
- Hepatitis A, 646, 647-648
- Hepatitis A vaccine, 656-657
- Hepatitis A virus, acute hepatitis due to, 436  
Centers for Disease Control and Prevention recommendation on, 435  
countries with endemicity for, 435  
infection with, management of, 444  
pre-exposure prophylaxis and, 435  
transmission of, factors increasing risk of, 435
- Hepatitis A virus vaccines, vaccination schedules for, 435, 436
- Hepatitis B vaccine, 646, 654-656, 661
- Hepatitis B virus, as cause of chronic hepatitis, 437  
carriers of, 437  
exposure to, assessment and emergency management of, 687-688  
management of, 691  
postexposure prophylaxis and, 686-687, 688-689, 690, 692  
reporting of, 686-687  
hepatitis C virus, and HIV disease, risk, prevention, and management of, **681-696**  
in hepatocellular carcinoma, 540  
infection with, treatment of, 444  
morbidity and mortality associated with, 645-646  
occupational transmission of, risk of, 683  
risk groups for, 437  
transmission of, 436
- Hepatitis B virus infection, vaccination against, 686
- Hepatitis B virus vaccine, recommended doses of, 438
- Hepatitis C, vaccine for, development of, 660-661
- Hepatitis C virus, chronic, 439  
exposure to, assessment and emergency management of, 687-688  
management of, 691-693  
postexposure prophylaxis and, 686-687, 688-689, 690  
reporting of, 686-687  
genotypes of, 440

- Hepatitis C virus (*continued*)  
  hepatitis B virus, and HIV disease,  
    risk, prevention, and  
    management of, **681-696**  
  incidence of, 439-440  
  infection with, management of,  
    444-445  
  neoplasms associated with, 540  
  occupational transmission of, risk of,  
    683-684  
  risk groups for, 438, 439  
  transmission of, 438
- Hepatitis D virus, 441  
  and hepatitis B virus infection, 441  
  genotypes of, 441
- Hepatitis Delta virus, 660
- Hepatitis E virus, 441-442  
  infection with, management of, 445
- Hepatitis F virus, 442  
  infection with, management of, 445
- Hepatitis G virus, 442-443  
  infection with, management of, 445
- Hepatocellular carcinoma, viruses in  
  development of, 540
- Herbal medicines, and surgical patient,  
  381-382, 383
- Herbal supplements, 252-254
- Herpes labialis, recurrent, 519-520
- Herpes simplex infections, diagnosis of,  
  cytology smears for, 521  
    immunomorphologic tests for,  
      521  
    serologic tests for, 522  
    virologic tests for, 520-521  
  primary, 518-519  
  recurrent, 519-520
- Herpes simplex virus(es), 540-541  
  types of, 518
- Herpes zoster, 522-524  
  acyclovir in, 523  
  and postherpetic neuralgia, 523-524  
  in immunocompromised patients, 523  
  symptoms of, 523
- Herpesvirus 6, human, 527  
  in immunocompromised patients,  
    527-528  
  treatment of, 528
- Herpesvirus 7, human, 528-529
- Herpesvirus-6B, roseola and, 527
- Herpesvirus infections, update on, **517-532**
- Herpesvirus type 8, neoplasia associated  
  with, 539-540
- Herpesviruses, characteristics of,  
  517-518
- Hispanic population, in United States,  
  41-43  
    oral health promotion for,  
      obstacles to, 43
- Hispanic subgroups, in New York City,  
  dental health status and treatment  
  needs of, **41-55**  
    study of, discussion of, 51-53  
    methods of, 43-44  
    results of, 44-51
- HIV, in neoplasms, 541-542
- HIV-associated Kaposi's sarcoma, oral  
  mucosal lesions of, 539  
  prevalance of, 541
- HIV disease, **467-492**  
  and tuberculosis, 454-455  
  antiretroviral drug-resistant  
    transmission of, 474  
  clinical staging of, 471  
  course of, and laboratory monitoring  
    of, 471  
  dental treatment considerations in,  
    483-486  
  dentists in diagnosis of, 470  
  diagnosis of, 470  
  exposure to, assessment and  
    emergency management of,  
    687-688  
    management of, 688  
    postexposure prophylaxis and,  
      686-687, 688-689, 690  
    reporting of, 686-687  
  hepatitis B virus, and hepatitis C virus,  
    risk, prevention, and  
    management of, **681-696**  
  hepatitis viral infections with, 475  
  medical management of, 472-475  
  occupational exposure to, 469  
  occupational transmission of, risk of,  
    682-683  
  opportunistic disease and, prevention  
    and treatment of, 474-475  
  oral mucosal lesions in, and  
    periodontal disease, 475-482  
  oral opportunistic diseases and,  
    478-481  
  pathogenesis of, 469-470  
  reporting of cases of, 467  
  salivary gland dysfunction in,  
    477-482  
  suppression of HIV viremia and,  
    472-475



- testing for, 470
  - transmission of, 469
    - by dentists, 746
    - hepatitis B virus immunization and, 747
    - prevention of, 747
    - vaccine for, development of, 661
  - HIV-infected children, oral manifestations in, **159-174**
    - discussion of, 168-172
    - study of, caries prevalence and incidence of, 164-165
      - demographics and, 160-161
      - dental caries analysis and, 161
      - methods of, 160-163
      - oral mucosal lesion analysis and, 162, 165-166
      - periodontal disease analysis in, 162, 166-168
      - statistical analysis and, 162-163
  - Hormone replacement therapy, 220
  - Hospital, inner-city public, population served by, 128
    - profile of, 128
  - Host defense, disorders affecting, 710-712
  - Human immunodeficiency virus. *See HIV disease.*
  - Humoral deficiencies, 713
  - Huntsville Study, 12
- 
- I**
- IgA deficiency, 712-714
  - IgG levels, *Porphyromonas gingivalis*, and low birth weight, 120, 121
  - Illness, human, in exposure to contaminated dental treatment water, 552-553
  - Immune defense, functional defects in, 720
  - Immune deficiency(ies), acquired, 715-727
    - antibiotic prophylaxis in, 727
    - common, 712-714
    - primary, 712-715
      - causes of, 712
  - Immune response, 710
  - Immune senescence, 348
  - Immune status, alterations in, persons at risk for, 348
  - Immune suppression, and considerations for dental care, **709-731**
  - Immune system, 710
    - and periodontal disease, 341-342
    - dysfunction of, results of, 710
  - Immune system, immunizations and, 641-645
  - Immunity, infection, and nutritional status, interaction of, 340-349
    - malnutrition and, 343
    - nutritional strategies to enhance, 350-351
  - Immunization(s), active, 644
    - and immune system, 641-645
    - for health care providers,
      - contraindications, precautions, and adverse reactions to, 657-658
    - health care providers and, **641-664**
    - indicated for oral health personnel, 645-646
    - passive, 644
    - process of, 643
    - terms associated with, 644
  - Immunocompetent states, immunologic events in, 710
  - Immunocompromised host, dental considerations in, 726-727
    - host integrity and, 723-724
    - oral health care for, 723
    - risk of infection in, 724
  - Immunocompromised patients, antibiotic prophylaxis for, 675
    - definition of, 709
    - management of, dental clinician and, 709
  - Immunodeficiency disease, common
    - variable, 714
    - severe combined, 714
  - Immunodeficiency(ies), acquired, 715
    - causes of, 716
    - combined, 713
  - Immunoglobulin abnormalities, pathogens associated with, 711
  - Immunoprophylaxis, recommended, for health care providers, 647, 648
  - Immunosuppressive drugs, posttransplant, 722-723
  - Infant, nutrition of, transition stage of, 284
    - with clefts, breast feeding and, 312-313
    - nutritional requirements of, 307-312

Infant formulas, fluoride content of, 234-235

Infection(s), aerosolized, protection against inhalation of, 461  
and cleaning, disinfection, and sterilization of patient care items, 699-700  
biofilm-mediated, 547  
cell-mediated immunity and, 718-719  
control of, **697-708**  
in health care settings, 704  
precautions in, 698-699  
program development for, 701-705  
program evaluation in, 706-707  
rationale for, 697-698  
Web-based resources for, 706  
effect on nutritional status, 346-348  
exposure to, prevention of, 699  
immunity, and nutritional status, interaction of, 340-349  
maxillofacial, bacterial cultures from, media for culture of, 611  
mortality due to, 623-624  
nutrition, and periodontal disease, **337-354**  
occupationally acquired, from airborne and bloodborne transmission, 642  
opportunistic, in immunocompromised host, 725  
oral, 360  
and systemic diseases, **575-598**  
oral metastatic, antibiotic prophylaxis for patients at risk for, 675  
prevention of, nutritional strategies for, 350-351  
risk of, in immunocompromised host, 724  
susceptibility to, in immunocompromised host, 724-725  
transplant recipient and, 721  
waterborne, dental office and, 545

Infectious disease, diagnosis of, laboratory methodologies for, 614-615  
diagnostic modalities for, **605-621**

Influenza, 646

Influenza vaccine, 653-654

Insurance, health, by race/ethnicity, 27-28

Integrins, 629

Intraoral and extraoral examination, in nutrition evaluation, 267-268

Iron deficiency, in children, 293-294

Isoniazid, in tuberculosis, 457  
side effects of, 461, 462

## K

Kaposi's sarcoma, 528  
epidemiologic forms of, 539  
HIV-associated, oral mucosal lesions of, 539  
prevalence of, 541  
malignant tumors induced by, 529  
pathogenesis of, 540  
sexual transmission of, 529

Kaposi's sarcoma-associated herpesvirus, neoplasia associated with, 539-540

Kava, 254

King/Drew Medical Center, 128

Koch's postulates, 533

Kostmann's syndrome, 717

Kuru, 498

## L

Labels, food, 190

Leukoplakia, hairy, 476, 477  
Epstein-Barr virus and, 527

Lip, recurrent herpes simplex infection of, 519-520

Lipids, dietary, 193-195

Long-term-care facilities, antibiotic resistant micro-organisms and, 624-625

Low birth weight, IgG levels, and *Porphyromonas gingivalis*, 120, 121  
in preterm infants, and periodontal disease among African Americans, studies of, 116-117  
discussion of, 121-123  
materials and methods in, 117-119  
results of, 119-121  
sample size and power in, 118  
statistical analyses in, 118-119  
and periodontal diseases, among African Americans, **115-125**  
definition of, 115  
predictors of, 120, 121  
periodontitis, 586-590

T-Lymphotropic 1 virus, human, neoplasia and, 541

Lysine, 246-247

**M**

- 
- Ma Huang, 251
- Magnetic resonance imaging, for diagnosis of Creutzfeldt-Jakob disease, 507
- Malignant disorders, and myelodysplasia, 719-720
- Malnutrition, and immunity, 343  
chronic, noma and, 565  
enamel hypoplasia associated with, 320
- Mandible, abscess of, gram-positive staphylococci in, 615
- Masks, to prevent transmission of tuberculosis, 461
- Maxillofacial infections, bacterial cultures from, media for culture of, 611
- Maxillofacial surgery, in Creutzfeldt-Jakob disease, 511
- Measles, 645, 649  
mumps, rubella vaccine, 649-651, 660  
noma and, 564, 565
- Medications, as influence on nutritional status, 358  
dietary supplements and, 265  
herbal, and surgical patient, 381-382, 383
- Meharry Medical College's School of Dentistry, 177, 178
- Meningococcal disease, 648
- Mercury, dental amalgam, 632
- Metabolic response, in response to surgery/injury, 374, 375
- Micro-organisms, antibiotic resistant, long-term-care facilities and, 624-625  
mechanisms for genetic variation, 628  
oral, bacterial endocarditis and, 669-670
- Microbial disease, diagnosis and treatment of, 606  
etiologies of, 605
- Microbial resistance, 624  
in oral cavity, 625-627
- Microbial specimens, collection and transport of, 606-610  
collection of, before antibiotic chemotherapy, 607  
blood cultures and, 607  
smear of fluid material and, 608  
swabs and containers for, 607  
transport of, 606-610  
commonly submitted, collection and transport of, 610, 612-613  
diagnostic techniques and methods for, 610-618  
Gram-stained patient abscess smears, 609  
results and laboratory evaluation of, reporting of, 618-620  
transport of, for laboratory analysis, 608-609
- Microbiologic flora, oral, 338-340
- Micronutrients, deficiencies of, and immune response, 343-346
- Microorganisms, periodontal disease due to, 339
- Milk, fluoridated, 231
- Minerals, 203-204  
dietary sources of, 200-201  
requirements for, 200
- Mink encephalopathy, transmissible, 495
- Minority populations, composition of whole saliva and caries experience in, **67-85**  
destructive periodontal diseases and, **103-114**  
oral health of, regional research centers for, legacy of, **175-181**  
research in. See *Research Centers, Regional, for Minority Oral Health*.  
recruitment of, to dental schools, 35  
underserved, orofacial injuries in, **127-139**
- Monocytes, 642
- Mother, transmission of *Streptococcus mutans* by, in African American population, **87-101**
- Mucositis, oral, pathogens associated with, 711
- Mumps, 645, 650-651
- Myelodysplasia, malignant disorders and, 719-720
- Myobacterium tuberculosis*, 449, 450
- 
- N**
- National Center for Bioethics, 11
- National Health and Nutrition Examination Survey, 58
- Needle devices, with engineered safety features, 685

- Neonates, infection with cytomegalovirus, 524
- Neoplasm(s), associated with Epstein-Barr virus, 538-539  
associated with hepatitis C virus, 540  
associated with herpesvirus type 8, 539-540  
associated with Kaposi's sarcoma-associated herpesvirus, 539-540  
epidemiology pattern of, 534  
growth of, viruses and, **533-543**  
HIV in, 541-542  
human papillomaviruses and, 535-536  
human T-lymphotrophic 1 virus and, 541  
pathogenesis of, 534-535  
viral etiology of, criteria for establishing, 533  
viruses linked to, 534
- Neuralgia, postherpetic, herpes zoster and, 522-524
- Neurohumeral mediators, in response to surgery/injury, 374
- Neutropenia, causes of, 716-717  
congenital causes of, 717  
definition of, 716  
immune-mediated, 717  
pathogens associated with, 711  
severe congenital, 717  
treatment-related, 717
- Neutrophils, 642
- New York University College of Dentistry, 58-59, 179
- Noma, as forgotten disease, **559-573**  
clinical presentation of, 561-563  
description of, 559  
diagnosis of, 562-563  
etiology and pathogenesis of, 563-567  
history of, 559-560  
incidence of, 560  
initial oral lesions and, 561  
lesions of, microbiota of, 565-566  
reconstructive surgery in, 568-569  
risk factors for acquiring, 564-565  
social and cultural aspects of society of source, 567  
survivors of, disfigurements in, 563  
treatment of, 567-569  
trigger organisms of, 566  
trismus associated with, 563, 567, 568  
World Health Organization noma network and, 569-570
- Noma neonatorum, 561
- Non-Hodgkin's lymphoma, in AIDS, 541-542
- Northeastern Minority Oral Health Research Center, 180
- Nutrients, 191-202  
antioxidant properties of, 205  
in oral tissues growth, development, and health, 202-205
- Nutrition, and dental caries, **319-336**  
and oral health, **187-207**  
and wound healing, 378-380  
definition of, 187  
diet and, evaluation of, 271-275  
in pediatric dentistry, **279-303**  
for health promotion, **411-423**  
for surgical patient, **373-393**  
gerodontic, for prosthodontic patients, **355-371**  
infection, and periodontal disease, **337-354**  
of older adults, optimizing of, 362-366  
plaque biofilm and, 339-340  
role of fluorides in, **225-243**
- Nutrition Labeling and Education Act of 1990, 190
- Nutrition-risk questions, 277-278
- Nutrition-risk screens, 260-262
- Nutritional screening, 259
- Nutritional status, clinical and laboratory assessment of, **259-278**  
effect of infection on, 346-348  
evaluation of, in surgical patient, 380-381  
immunity, and infection, interaction of, 340-349  
laboratory tests to assess, 268-271  
medical history and, 263-265  
of older adults, 355-356  
patient history and, 262-263  
physical assessment of, 265-268  
systemic diseases associated with, 263, 269
- Nutritional supplements, 246-250  
definition of, 246  
ergogenic acids, and herbals, **245-258**  
uses and concerns for dental practitioner, 248-249
- Nutritional support, for surgical patient, 386-389

**O**

- 
- Obesity, childhood, 289–291  
     dental treatment in, 391–392  
     diets to combat, 415–421
- Occupational exposure, to contaminated dental treatment water, 552
- Older adults, dental health of, 360  
     nutritional status of, 355–356  
     optimizing diet and nutrition in, 362–366
- Oral cavity, bacteremias and, 668–669  
     microbial resistance in, 625–627
- Oral fluids, testing for antibodies, in diagnosis of HIV disease, 470
- Oral health, dietary habits and, 294–297  
     minority, regional research centers for, legacy of, **175–181**  
     nutrition and, **187–207**  
     status of, determination of, conceptual framework for, 23–24
- Oral health care, for immunocompromised host, 723
- Oral health care setting, diseases with predilection for transmission in, 647
- Oral health service, utilization of, and oral health status, factors affecting, 30, 31–33
- Oral health status, utilization of oral health service and, factors affecting, 30, 31–33
- Oral infections, and systemic diseases, **575–598**
- Oral mucosal lesions, analysis of, in HIV-infected children, 162  
     HIV-associated, and periodontal disease, 475–482  
     of HIV-associated Kaposi's sarcoma, 539  
     of tuberculosis, 453–454
- Orofacial injury(ies), in underserved minority populations, **127–139**  
     and associated risk factors, 132–135  
     and recurrent injury, 135–136  
     discussion of, 136–137  
     nature of injuries and, 131–132  
     patient sociodemographics and, 130–131  
     socioeconomic impacts of, 132  
     spectrum of, 129  
     studies of, background of, 128  
         methods of, 129–130  
         results of, 130–136

- substance use and, 133, 135  
     incidence of, in urban African American population, 141  
     psychosocial sequelae of, 145–152  
     and correlates of, **141–157**  
     study of, 142–156  
         clinical implications  
             observed in, 155–156  
         patient characteristics in, 143  
         patient compliance and, 153–154  
         risk factors for injury and recurrent injury and, 143  
         showing psychological distress, 144  
         support needs during recovery and, 152–153  
     University of California-LA/Drew Regional Research Center for Minority Oral Health Experience investigations, 142–156

Orthognathic surgery, dietary considerations and, 384–385

Osteoblasts, 214–215

Osteocytes, 215

Osteoporosis, calcium and, 219–221  
     diet and, 293  
     treatment of, 220–221

**P**

- 
- Papillomaviruses, human, 535–538  
     and neoplasia, 535–536  
     lesions of, cells of, 537  
     malignant potential of, 536  
     replication of, 536
- Parathyroid hormone, and calcitonin, effects on bone, 215, 216  
     calcium in plasma and, 213
- Parenteral nutrition, total, for surgical patient, 388
- Pathogens, waterborne, and dental waterlines, **545–557**
- Patient care items, and environmental surfaces, categories of, 700  
     cleaning, disinfection, and sterilization of, infections and, 699–700
- Patient(s), illness of, due to exposure to contaminated dental treatment water, 552–553

- Patient(s) (*continued*)  
transmission of tuberculosis to, 460  
with tuberculosis, management of, 458-462
- Pediatric dentistry, diet and nutrition in, **279-303**
- Pediatrics. See also *Child(ren)*.  
dietary counseling in, 297-300
- Penicillin, 623  
allergy to, 674  
viridans group streptococci resistance to, 673
- Percutaneous injury, risk of, 684  
postexposure prophylaxis in, 690
- Periodontal disease(s), AIDS and, 160  
analysis of, in HIV-infected children, 162  
and HIV-associated oral mucosal lesions, 475-482  
bacterial endocarditis and, 669  
bone health and, 215  
causes of, 159  
destructive, clinical and demographic parameters and, according to ethnic/racial group, 107, 108  
in minority populations, **103-114**  
incidence and progression of, 104-109  
risk indicators and risks associated with, 109-112  
Surgeon General's report on, 103-104  
dietary calcium and, 217  
immune system and, 341-342  
in eating disorders, 404  
in HIV disease, 482, 483  
microorganisms associated with, 339  
nutrition, and infection, **337-354**  
preterm low birth weight and, among African Americans, **115-125**  
systemic diseases influencing, 575  
vitamin C and, 247-250
- Periodontitis, 337-338  
and diabetes mellitus, 585-586  
treatment of, 586  
cardiovascular disease and, 575-577  
epidemiologic studies in, 576, 578-579, 580, 581  
treatment of, 577  
low birth weight and, 586-590  
preterm birth and, 586-590  
rheumatoid arthritis and, 584-585  
treatment of, 585
- Periodontium, effects of dietary intake on, 349-351
- Phagocytic deficiencies, 713
- Phagocytic dysfunction, 718
- Pharyngitis, pharyngeal exudate in, 616
- Phytochemicals, compounds included in, 413  
functions of, 413-414  
health promoting effects of, 413
- Pica, 292
- Plant foods, as anticariogenic agents, 326-327
- Plaque biofilm, 338-339  
host nutrition and, 339-340
- Plasma, calcium in, 212-213  
parathyroid hormone and, 213
- Plasmids, 628-629
- Pneumocystic carinii pneumonia, HIV disease and, 474-475
- Pneumonia, and oral bacteria, 583-584  
therapeutic consequences of, 584  
community-acquired, 583  
hospital-acquired, 583-584
- Porphyromonas gingivalis*, IgG levels, and low birth weight, 120, 121
- Posttraumatic stress disorder symptoms, following orofacial injuries, 146, 147, 148, 149, 150, 151
- Pregnancy, effect of, on maternal levels of *Streptococcus mutans*, 95
- Preterm birth, periodontitis and, 586-590
- Preterm infants, low birth weight, and periodontal diseases, among African Americans, **115-125**
- Prion diseases. See *Encephalopathy(ies)*, *transmissible spongiform*.
- Prions, and human transmissible spongiform encephalopathies, **493-516**  
description of, 493, 505  
in human trigeminal nerve and oral tissue, 504-505  
locations of, detection of, animal studies of, 496  
transmission by dental route, animal studies of, 496
- Prosthetic patients, gerodiatric nutrition and dietary counseling for, **355-371**
- Protein(s), complete, 196

dietary, 195-197  
     inadequate intake of, 196  
 serum-circulating, nutritional status  
     and, 381

Protein energy malnutrition, and failure to  
 thrive, 288-289

Provitamin, 199-200

Psychosocial sequelae, of orofacial injuries,  
 psychosocial sequelae of, and  
 correlates of, **141-157**

Pyrazinamide, in tuberculosis, 457  
 side effects of, 462

Pyrogenic reactions, 551

## R

---

Ramsay-Hunt syndrome, 523

Recommended dietary allowances, 187, 189

Regional Research Centers for Minority  
 Oral Health. See *Research Centers,  
 Regional, for Minority Oral Health.*

Research Centers, Regional, for Minority  
 Oral Health, 21, 30, 31, 32, 58, 127,  
 175, 181

    meetings of, 176-177

Research centers, Regional, for minority  
 oral health, goals of, 176  
 legacy of, **175-181**

Research issues, 254

Retroviruses, 541

Reye's syndrome, 522

Rheumatoid arthritis, and periodontitis,  
 584-585  
     treatment of, 585

Rifampin, in tuberculosis, 457  
 side effects of, 461-462

RNA oncogenic viruses, 541

Roseola, human herpesvirus-6B and, 527

Rubella, 645, 651

Rumination, 292

## S

---

Saliva, as complex secretion, 74-75  
     function of, 320  
     functions of, 67  
     whole, caries prediction and, protocol  
     for, 76  
     cariogenic organisms in, 68

    collection of, 68  
     composition of, and caries  
     experience, in minority  
     populations, **67-85**  
     microbiological assay of, 68-69  
     results of, 69-74  
     statistical analyses of, 69  
     pathogenic bacteria in, by  
     ethnicity, 71, 72-73  
     study(ies) of, discussion of, 74-82  
     materials and methods for,  
     68-69  
     participants in, 68, 70  
     smoking by participants in,  
     and socioeconomic  
     status, 68, 70

Salivary glands, dysfunction of, in HIV  
 disease, 477-482  
     hypertrophy of, in eating disorders,  
     404

Salt, fluoridated, 230-231

Scrapie, 493, 495

Scrapielike spongiform encephalopathy, 495

Screening enzyme immunoassay, 470

Sepsis, 719

SMA panel, 271-273

Smallpox, 738-740  
     course of disease, 739  
     in United States, 738  
     spread of, 739  
     vaccination against, 739-740  
     contraindications to, 740

Soft tissue, lesions of, in eating disorders,  
 405

Spaulding classification scheme, of patient  
 care items, 699-700

Splenectomy, pathogens associated with,  
 711

Spongiform encephalopathies,  
 transmissible. See  
*Encephalopathy(ies), transmissible  
 spongiform.*

Squamous cell carcinoma, human  
 papillomavirus and, 536, 538

Stature, assessment of, in children, 280

Sterilization, methods of, 702-703  
     of patient care items, infections and,  
     699-700

Steroids, anabolic, 251

Stool, calcium excretion in, 218-219

*Streptococcus mutans*, epidemiology of, 88-92  
 findings from cross-sectional study, 89-90  
 findings from longitudinal studies, 90-92  
 maternal levels of, effect of pregnancy on, 95  
 maternal transmission of, effect of chlorhexidine treatment on, 96-97  
 effect of delivery on, 95-96  
 fidelity of, 93-95  
 in African American population, **87-101**  
 maternal attributes to, 95-97  
 prevalence of, in African American children, 89  
 in different ethnic populations, 88-89  
 transmission of, 92-93

*Streptococcus viridans*, antibiotic resistance of, 673  
 bacterial endocarditis and, 668, 669

*Streptococcus pneumoniae*, mortality due to, 625

Streptomycin, in tuberculosis, 457  
 side effects of, 462

Sugar(s), accusations against, 192-193  
 carbohydrates, and sweeteners, caries-promoting potential of, 322, 323  
 forms of, in processed foods, 193

Sugar substitutes, caries-promoting potential of, 326

Supplements. See also *Dietary supplement(s)*; *Nutritional supplements*.  
 interactions of, 254-255  
 questions regarding use of, 255

Surgical patient, evaluation of nutritional status in, 380-381  
 herbal medicines and, 381-382, 383  
 nutritional considerations in, **373-393**  
 nutritional support for, 386-389

Sweeteners, alternative, 193  
 carbohydrates, and sugars, caries-promoting potential of, 322, 323  
 caries-promoting potential of, 326

Syphilis, untreated, in African American male, study of, 4-5

Systemic diseases, associated with nutritional status, 263, 269  
 oral infections and, **575-598**

Systemic inflammatory response syndrome, 719

## T

T-cells, 643

Taste and smell, as influence on nutritional status, 359-360

Tea tree oil, 253-254

Teas, caries prevention and, 327

Tetanus-diphtheria injections, 645

Tetanus vaccine, 652-653

Tetracycline, antibiotic resistant genes and, 632

Tobacco use, carcinomas associated with, 537-538

Tooth(Teeth), calcium in, 215-217  
 development of, nutrition and, 204  
 erosion of, in eating disorders, 400-402, 403

Trace minerals, 200

Transfusion-transmitted virus, 443

Transmissible spongiform encephalopathies. See *Encephalopathy(ies)*, *transmissible spongiform*.

Transplant recipient, cellular immunity and, 721  
 immune status of, 720  
 infections and, 721  
 medications taken by, 722

Trauma surgery, dietary considerations and, 385

Triglycerides, 194

Trismus, associated with noma, 563, 567, 568

Tuberculin, old, 455

Tuberculin skin testing, 456

Tuberculosis, **449-465**, 647  
 as global, 449  
 extrapulmonary, manifestations of, 452  
 granulomatous inflammation in, 451  
 history of, 449  
 HIV disease and, 454-455, 475



incidence of, 449-450  
 management of, 455-458  
 management of dental patient with, 458-462  
 military, 453  
 of head and neck, 453  
 oral manifestations of, 453-454  
 pulmonary manifestations of, 451  
 reactivation of, 451-452  
 secondary, 451  
 testing for, 456  
 transmission of, 450-453  
   barrier techniques to prevent, 460-461  
   Centers for Disease Control and, 458  
   dental workers and, 459-460  
   dentist-to-patient, 460  
   in health care facility, risk categories for, 460  
 treatment of, 456-458  
 vaccination in, 455

Tuberculosis vaccine, 657

Tuskegee Legacy Project, 1-19, 180  
   3 City study, 13-14  
   4 City study, 14-15  
   and additional pilot summer studies, 12-13  
   legacy of, 15  
   origins of, 1-3  
   proposed, significance of, 8-9  
   questionnaire, development at workshop, 10-11  
   summer pilot studies to develop, 9-10  
   unanticipated societal benefits of, 11-12

Tuskegee syphilis study, background of, 3-8

## U

Ubiquinone, 250

United States Food and Drug Administration (FDA), 705

University of California in Los Angeles, 127

University of California-LA/Drew Regional Research Center for Minority Oral Health Experience, investigations of orofacial injuries, 142-156

Urine, calcium excretion in, 217-218

## V

Vaccination, against hepatitis B virus infection, 686

in tuberculosis, 455  
 origin of term, 643

Vaccine(s), composition of, 644  
   for immunocompromised health care providers, 658-660  
   synthetic, 645  
   tuberculosis, 657

Valerian, 254

Vancomycin-resistant enterococci, 624

Varicella, 522

Varicella vaccine, 645, 651-652

Varicella zoster virus, 522-524

Verrucous carcinoma, human papillomavirus and, 537-538

Viridans group streptococci, bacteremias, 626  
   beta-lactam antibiotics and, 626

Virus(es), and neoplastic growth, 533-543  
   classification of, 533-534  
   DNA oncogenic, 535-541  
   RNA oncogenic, 541

Vitamin A, importance of, 205

Vitamin C, deficiency of, effects of, 205  
   periodontal disease and, 247-250

Vitamins, bioavailability of, 199  
   classification of, 200, 201-202  
   in foods, forms of, 199-200

Vomiting, chronic, oral symptoms of, 401

## W

Water, as essential nutrient, 197  
   bottled, purity of, 199  
   sources of, 199  
   clean, treatments to produce, 198-199  
   daily requirements of, 197, 199  
   dietary sources of, 197  
   drinking, sources of, 198  
   fluorination of, 226-227  
   effectiveness in caries prevention, 227-228  
   opposition to, 228-229

Water bacteria, gram-negative heterotrophic, 546

Water systems, dental unit, contamination of, 548-553  
   methods to control, 553  
   sources of biofilm in, 548

Waterlines, dental, and health, 548–553  
    biofilms in, 547–548  
        diseases caused by, 550  
        portals of entry of, 550  
    design of, biofilms and, 547–548  
    organisms in, potential  
        pathogenicity of, 549  
    waterborne pathogens and,  
        **545–557**

Weight, assessment of, in children, 280

Weight-for-height ratio/body mass index,  
    for children, 280–281

World Health Organization noma network,  
    noma and, 569–570

Wound healing, 374–378  
    nutrition and, 378–380

---

**X**

---

Xerostomia, cariogenic bacteria and, 320  
    causes of, and dental problems caused  
        by, 359  
    due to chemotherapy, 386  
    in eating disorders, 403

---

**Y**

---

Yohimbe, 253